Brief: Artivion Q2 Revenue USD 112.972 Million Vs. IBES Estimate USD 108 Million

Artivion

07/08/2025 21:05

Overview

Artivion Q2 revenue rises 15% yr/yr, beating analyst expectations, per LSEG data

Adjusted net income for Q2 beats consensus, reflecting strong operational performance

Co exchanged $99.5 mln in convertible notes for common stock, improving capital structure

Outlook

Artivion raises full-year revenue guidance to $435 mln-$443 mln

Company expects constant currency revenue growth of 12%-14% in 2025

Artivion increases adjusted EBITDA guidance to $86 mln-$91 mln

Company anticipates adjusted EBITDA growth of 21%-28% for 2025

Result Drivers

PRODUCT LINE GROWTH - Revenue growth driven by 24% increase in On-X and stent grafts, per CEO Pat Mackin

CAPITAL STRUCTURE IMPROVEMENT - Exchange of $99.5 mln in convertible notes for common stock, effectively retiring debt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$112.97 mln
$108 mln (7 Analysts)
Q2 Adjusted Net Income
Beat
$10.70 mln
$65,000 (6 Analysts)
Q2 Net Income
$1.34 mln
Q2 EBIT
$8.38 mln
Q2 Operating Expenses
$64.73 mln
Q2 Pretax Profit
$3.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Artivion Inc is $33.00, about 2.2% above its August 6 closing price of $32.27

The stock recently traded at 105 times the next 12-month earnings vs. a P/E of 165 three months ago

Press Release: ID:nPn44Q24va

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)